News

Sarepta Stock Soars 30%. Why Layoffs and a ‘Black-Box’ Warning Are Good News.
Sarepta Therapeutics stock soared over 30% after the pharmaceutical company said it would lay off about 500 employees. It ...
BioPharma Dive16h
Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks
The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.
GEN - Genetic Engineering and Biotechnology News9h
Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths
Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the ...
BioSpace14h
Sarepta Tags DMD Gene Therapy Elevidys With Black Box Warning, Axes 500 Staff
Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...
Stocktwits on MSN10h
Sarepta Surges After-Hours As It Slashes 500 Jobs Amid FDA Black Box Warning For Gene Therapy — Retail Eyes Rebound
Sarepta Therapeutics shares surged 34% in after-hours trading on Wednesday after the company said it would slash 500 jobs, or ...
Fierce Biotech15h
Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning
This story was updated at 5:30 p.m. ET to include comment from an investor call.   | Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring ...
JPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 10, ...